Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.64 |
| ▸ | CNR2 | P34972 | 2/20 | 0.62 |
| ▸ | CFD | P00746 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | PDE1A | P54750 | 1/20 | 0.52 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.52 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | PHGDH | O43175 | 1/20 | 0.48 |
| ▸ | CTSA | P10619 | 1/20 | 0.48 |
| ▸ | SELP | P16109 | 1/20 | 0.47 |
| ▸ | SELE | P16581 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3054511 | 0.92 | CNR2 (0.58) | PDE5ACNR2CFDNR1H4PPARG | |
| SCHEMBL3057330 | 0.91 | CNR2 (0.74) | PDE5ACNR2CFDNR1H4PPARG | |
| SCHEMBL3065626 | 0.91 | PDE5A (0.56) | PDE5ACNR2CFDNR1H4PPARG | |
| SCHEMBL3054077 | 0.90 | CNR2 (0.56) | PDE5ACNR2CFDNR1H4PPARG | |
| SCHEMBL3067836 | 0.89 | CNR2 (0.61) | PDE5ACNR2CFDNR1H4PPARG | |
| SCHEMBL3054629 | 0.89 | CNR2 (0.60) | PDE5ACNR2CFDNR1H4PPARG | |
| SCHEMBL3053827 | 0.85 | CNR2 (0.54) | PDE5ACNR2CFDPOLBPDE1A | |
| SCHEMBL13088637 | 0.84 | CNR2 (0.58) | PDE5ACNR2CFDPOLBPDE1A | |
| SCHEMBL5785702 | 0.84 | CNR2 (0.78) | CNR2POLBCTSAALDH1A1SMN1; SMN2 | |
| SCHEMBL3054920 | 0.81 | MAPT (0.72) | PDE5ANR1H4PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662839-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-02-16 | — | — | US | claimed |
| US-20100261760-A1 | EP2 Receptor Agonists | ASTERAND UK LIMITED (GB) | 2010-10-14 | — | — | US | disclosed |
| US-20100261760-A1 | EP2 Receptor Agonists | ASTERAND UK LIMITED (GB) | 2010-10-14 | — | — | US | disclosed |
| US-20100261760-A1 | EP2 Receptor Agonists | ASTERAND UK LIMITED (GB) | 2010-10-14 | — | — | US | disclosed |
| US-7803841-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7803841-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7803841-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7662839-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| US-7662839-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| US-7662839-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| US-20090298899-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED | 2009-12-03 | — | — | US | disclosed |
| US-20080119526-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders; e.g. {4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl}-acetic acid | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| US-20080119526-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders; e.g. {4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl}-acetic acid | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| US-20080119526-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders; e.g. {4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl}-acetic acid | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| US-7326732-B2 | EP2 receptor agonists | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-02-05 | — | — | US | disclosed |
| US-7326732-B2 | EP2 receptor agonists | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-02-05 | — | — | US | disclosed |
| US-7326732-B2 | EP2 receptor agonists | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-02-05 | — | — | US | disclosed |
| EP-1723132-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20050256170-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); e.g. (4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl)-acetic acid or 5-Phenyl-furan-2-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide; dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders | ASTERAND, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005080367-A1 | EP2 RECEPTOR AGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298899-A1 | EP2 RECEPTOR AGONISTS | PTGER2, PTGER1, TBXA2R | PDE5A 872/4885CNR2 13/4885CFD 4470/4885 |
| US-20080119526-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders; e.g. {4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl}-acetic acid | PTGER3, PTGER4, PTGES3 | PDE5A 1545/4885CNR2 55/4885CFD 873/4885 |
| US-20100261760-A1 | EP2 Receptor Agonists | PTGER2, PTGER1, TBXA2R | PDE5A 872/4885CNR2 13/4885CFD 4470/4885 |
| US-20050256170-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); e.g. (4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl)-acetic acid or 5-Phenyl-furan-2-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide; dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders | PTGER3, PTGER1, PTGER4 | PDE5A 1413/4885CNR2 43/4885CFD 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.